July 18, 2013
Plandaí’s Phytofare Is The Smart Way To Go
Green tea and green tea extracts are some of the most popular products in the nutraceutical market due to their widely publicized beneficial health properties. Specifically, green tea’s gallate catechins are known to have been used extremely effectively and efficiently as an antioxidant, a weight loss aid, cold prevention, oral health, and cardiovascular health. The most dominant catechin, Epigallocatechin Gallate (EGCG) is also applied to medicinal treatments for HIV/AIDS, cancer, malaria, chronic fatigue syndrome, and others. Given the breadth and depth of applications, the growth rate in the space remains high and Plandaí Biotechnology, Inc. (OTCQB – PLPL - $0.43 – Spec Buy) is primed to take advantage of the offering’s increased demand. In fact, today, EGCG is used in such products as dietary supplements, herbal tea, energy drinks, functional foods, and cosmetics and associated creams.
ECGC is one of the most well researched extracts in the natural extract sector, with over 500 validated research studies published worldwide. Moreover, the market for green tea remains in a strong growth trajectory with increasing volume growth rates between 13-14% per year annually, and generating roughly $50 billion in sales each year. While much of the attention of the use of these nutrients is on wellness and disease prevention, Plandaí’s flagship product, Phytofare™ Catechin Complex, might prove its effectiveness in increasing our cognitive abilities as well.
Studies and research performed in the 1990’s in recent years confirmed the fact that due to EGCG’s ability to easily cross the blood brain barrier and increasing brain activity up to 2 hours after ingestion, EGCG’s cognitive properties have been investigated in animal studies. When administered via IV to rats, EGCG statistical significance was witnessed at high doses one hour prior to a learning event. Plus, lower doses fed orally for eight weeks indicated an improvement in memory in aged rates.
Moreover, a study using a combination of green tea catechins and L-theanine, a constituent of green tea, demonstrated that patients suffering from non-clinical memory decline (average age 58) increasing recognition speed, word reading, and selective attention.
Clearly, whether EGCG is used alone or in conjunction with L-theanine, cognitive abilities can be aided via consumption of these nutrients. This opens up a whole new market for a company such as Plandaí that has demonstrated an ability to generate substantial bioavailability in botanical extracts, including green tea, which is key in leveraging the huge opportunity with Baby Boomers, the aging, and the younger set, which are prime targets for wellness and cognitive health.
You Might Also Like
Senior Analyst: Robert Goldman
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.